Diabetes mellitus - How to prevent macrovascular disease?

Journal fur Kardiologie

Volumn 10, Issue 4, 2003, Pages 149-151

  Wascher, Thomas C ^a  

^a UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SULFONYLUREA DERIVATIVE;

ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CARDIOTOXICITY; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DIABETES CONTROL; DISEASE ASSOCIATION; EARLY DIAGNOSIS; HEART INFARCTION; HUMAN; INCIDENCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; TREATMENT PLANNING; VASCULAR DISEASE;

EID: 0037247747     PISSN: 10240098     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Group DS. Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data. BMJ 1998; 317: 371-5.
2. Kannel WB, Lipids, diabetes and coronary heart disease: Insights from the Framingham study. Am Heart J 1985; 110: 1100-7.
3. Stratton IM, Adler AI, Neil AW, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycemia with macrovascular and microvascular complications of type-2 diabetes: prospective observational study. BMJ 2000; 321: 405-12.
4. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laasko M. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-34.
5. Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR, Wiedmeyer HM, Byrd-Hold DD. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. Diabetes Care 1998; 21: 518-24.
6. Adler AI, Stratton IM, Neil AW, Yudkin JS, Matthews DR, Cull CA, Wright AD, Turner RC, Holman RR. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321: 412-9.
7. Garcia MJ, McNamara PM, Gordon T, Kannel WB. Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study. Diabetes 1974; 23: 105-11.
8. Singer DE, Nathan DM, Anderson KM, Wilson PWF, Evans JC. Association of HbA1c with prevalent cardiovascular disease in the original cohort of the Framingham heart study. Diabetes 1992; 41: 202-8.
9. Turner RC, Millns H, Neil AW, Stratton IM, Manley SE, Matthews DR, Holman RR. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study. BMJ 1998; 316: 823-8.
10. Haffner SM, Alexander CM, Cook TJ, Boccuzzi SJ, Musliner TA, Pedersen TR, Kjekshus J, Pyörälä K. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels. Arch Int Med 1999; 159: 2661-7.
11. Goldberg RB, Mellies MJ, Sacks FM, Moye LA, Howard BV, Howard WJ, Davis BR, Cole TC, Pfeffer MA, Braunwald E. Cardiovascular events and their reduction with pravastatin in diabetic and glucose intolerant myocardial infarction survivors with average cholesterol levels. Circulation 1998; 98: 2513-9.
12. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaeffer EJ, Schectman G, Wilt TJ, Wittes J. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999; 341: 410-8.
13. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals. Lancet 2002; 360: 7-22.
14. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106.
15. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomized trial. Lancet 1998; 351: 1755-62.